Goldman Sachs said – these two shares can increase directly by 28 percent:

News Topical, Digital Desk : Brokerage Stock Report: Brokerage firm Goldman Sachs has adopted a bullish stance on two companies. Goldman initiated coverage on Max Healthcare with a 'Buy' rating and a target price of ₹1,325. This target implies a potential upside of approximately 20% from current levels. Goldman says Max's strong growth trajectory will be supported by 23% revenue and 24% EBITDA CAGR over the next few years, driven primarily by bed expansion.

The brokerage also cited Max's industry-leading profitability metrics, driven by operational efficiency. A strong balance sheet and free cash flow profile suggest the company has the largest capacity expansion potential in the sector. This potential is why Goldman Sachs has placed Max Healthcare on its buy radar.

What happened in the stock market that caused the Sensex to fall 450 points, while the Nifty neared 26,000?

KIMS Shares Expected to Rise 28%? Goldman Sachs has also initiated coverage on Krishna Institute of Medical Sciences (KIMS) and assigned it a 'Buy' rating. A target price of ₹900 for KIMS indicates a potential upside of 28% from current levels. The company is expected to deliver industry-leading revenue growth at a CAGR of 30% from FY2025 to FY2028, driven primarily by the ramp-up of new hospitals. Goldman believes that KIMS will have the greatest potential for margin expansion as losses from new units decline. The brokerage also stated that KIMS will be positioned to achieve top-quartile return ratios with a return on equity of approximately 25% after stable operations.